Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 4,023 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part 3 Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Effectiveness of Physician-assisted Versus Self-assisted Pap Smear Collection

NCT06229275
View directory record Official record
Conditions
Cervical Cancer Screening
Interventions
Pap smear collection using the Personal Pap Smear (PPS) Device, Active Comparator: Pap smear collection using the Rovers Cervex-Brush
Device
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 2Phase 3 Interventional Results available

Allogeneic Transplantation For Severe Osteopetrosis

NCT00775931
View directory record Official record
Conditions
Severe Osteopetrosis
Interventions
umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation
Procedure · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Day to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 2 Interventional Results available

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

NCT00399529
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Allogeneic GM-CSF-secreting breast cancer vaccine, Trastuzumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 1Phase 2 Interventional Results available

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

NCT03455829
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer
Interventions
G1T38, Osimertinib
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

NCT01031472
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK2248761 formulation 1, GSK2248761 reference formulation, GSK2248761 formulation 3, GSK2248761 formulation 2 or 4
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

NCT06945419
View directory record Official record
Conditions
Healthy, Overweight, Obesity, Type 2 Diabetes
Interventions
LY4086940, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Daytona Beach, Florida • Miami, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 13, 2026, 5:37 PM EST
Terminated Phase 3 Interventional Results available

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

NCT02322281
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Bakersfield, California • Duarte, California • Fullerton, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Nov 13, 2026, 5:37 PM EST
Completed Not applicable Interventional

Daughters, dUdes, Mothers and othErs Fighting Cancer Together

NCT04132219
View directory record Official record
Conditions
Cancer, Overweight and Obesity
Interventions
eHealth Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Nov 13, 2026, 5:37 PM EST
Terminated Not applicable Interventional

Ultrasound for Diagnosis of Biliary Dyskinesia

NCT00737295
View directory record Official record
Conditions
Biliary Dyskinesia
Interventions
CCK Injection and Ultrasound
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Nov 13, 2026, 5:37 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Smoke-free Home Intervention in Permanent Supportive Housing

NCT04855357
View directory record Official record
Conditions
Smoking Cessation, Second Hand Tobacco Smoke
Interventions
Resident counselling, Staff Training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 2 Interventional Results available

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

NCT04699630
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions
U3-1402
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Springdale, Arkansas • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Berkeley, California • Fresno, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Nov 13, 2026, 5:37 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pedal@Work: A Worksite Wellness Program

NCT01371084
View directory record Official record
Conditions
Physical Activity
Interventions
Pedal@Work Worksite Wellness, Pedal@Work
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Nov 13, 2026, 5:37 PM EST
Not listed Phase 1Phase 2 Interventional

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

NCT01541332
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Burbank, California • Encinitas, California • Fresno, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 1 Interventional

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

NCT03763149
View directory record Official record
Conditions
Advanced Malignancies
Interventions
IBI188
Biological
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Grand Rapids, Michigan • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Nov 13, 2026, 5:37 PM EST
Completed Not applicable Interventional Results available

Depression Attention for Women Now (The DAWN Study)

NCT01096316
View directory record Official record
Conditions
Depressive Disorder
Interventions
Depression Care Management
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 1Phase 2 Interventional Results available

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT03081858
View directory record Official record
Conditions
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions
TSD-001
Drug
Lead sponsor
Lipac Oncology LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Nov 13, 2026, 5:37 PM EST
Terminated Phase 1Phase 2 Interventional

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT04113616
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Interventions
KRT-232, Cytarabine, Decitabine
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 2 Interventional Results available

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

NCT03451084
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ASLAN003
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

NCT03441984
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 1Phase 2 Interventional

I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

NCT00802347
View directory record Official record
Conditions
Delayed Graft Function, Other Complication of Kidney Transplant
Interventions
I5NP, Saline
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Nov 13, 2026, 5:37 PM EST
Not listed Phase 1 Interventional

A Study of PSB205 in Subjects With Advanced Solid Tumors

NCT03986606
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
PSB205
Biological
Lead sponsor
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Nov 13, 2026, 5:37 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

NCT06656390
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumors
Interventions
ALK201
Drug
Lead sponsor
Shanghai Allink Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Denver, Colorado • Orlando, Florida • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 13, 2026, 5:37 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

NCT05054374
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
Interventions
Mirdametinib, Fulvestrant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Nov 13, 2026, 5:37 PM EST